Россия
Россия
Россия
Россия
В обзоре обобщены данные о применении ингибиторов натрий- глюкозного котранспортера 2-го типа с целью кардиопротекции у пациентов, принимающих потенциально токсичную противоопухолевую терапию; систематизированы результаты новых клинических исследований.
антрациклины, ингибиторы натрий-глюкозного котранспортера 2-го типа (иНГЛТ-2), кардиоонкология, кардиопротекция, кардиотоксичность, противоопухолевая терапия.
1. Lyon A.R., López-Fernández T., Couch L.S., Asteggiano R., Aznar M.C., Bergler-Klein J. et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS) // Eur Heart J. – 2022; 43:4229–361. https: //doi.org/10.1093/eurheartj/ehac244
2. Chazova I.E., Ageev F.T., Aksenova A.V., Vicenya M.V., Gilyarov M.Yu., Martynyuk T.V. et al. Eurasian clinical guidelines for cardiovascular complications of cancer treatments: diagnosis, preventio and treatment // Eurasian Heart Journal. – 2022:6–79. https: //doi.org/10.38109/2225-1685-2022-1-6-79
3. Herrmann J., Lenihan D., Armenian S., Barac A., Blaes A., Cardinale D. et al. Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement // Eur Heart J. – 2022; 43:280–99. https: //doi.org/10.1093/eurheartj/ehab674
4. Vafa R.G., Sabahizadeh A., Mofarrah R. Guarding the heart: How SGLT-2 inhibitors protect against chemotherapy-induced cardiotoxicity // Curr Probl Cardiol. – 2024; 49:102350. //doi.org/10.1016/j.cpcardiol.2023.102350
5. Peresada A.K., Dundua D.P., Kedrova A.G., Oleynikova I.N., Masterkova A.V. Cardioprotection of cancer patients receiving cardiotoxic chemotherapy – current status // Journal of Clinical Practice. – 2024; 14:75–87. https: //doi.org/10.17816/clinpract567924
6. Fabiani I., Chianca M., Cipolla C.M., Cardinale D.M. Anthracycline-induced cardiomyopathy: risk prediction, prevention and treatment // Nat Rev Cardiol. – 2025 https: //doi.org/10.1038/s41569-025- 01126-1
7. Waliany S., Lee D., Witteles R.M., Neal J.W., Nguyen P., Davis M.M. et al. Immune Checkpoint Inhibitor Cardiotoxicity: Understanding Basic Mechanisms and Clinical Characteristics and Finding a Cure // Annu Rev Pharmacol Toxicol. – 2021; 61:113–34. https: //doi.org/10.1146/annurev-pharmtox- 010919-023451
8. Ganesh S., Zhong P., Zhou X. Cardiotoxicity induced by immune checkpoint inhibitor: The complete insight into mechanisms, monitoring, diagnosis, and treatment // Front Cardiovasc Med. – 2022; 9:997660. https: //doi.org/10.3389/fcvm.2022.997660
9. Wu Q., Bai B., Tian C., Li D., Yu H., Song B. et al. The Molecular Mechanisms of Cardiotoxicity Induced by HER2, VEGF and Tyrosine Kinase Inhibitors: an Updated Review // Cardiovasc Drugs Ther. – 2022; 36:511–24. https: //doi.org/10.1007/s10557-021-07181-3.
10. Livingston K., Schlaak R.A., Puckett L.L., Bergom C. The Role of Mitochondrial Dysfunction in Radiation-Induced Heart Disease: From Bench to Bedside // Front Cardiovasc Med. – 2020; 7 https: //doi.org/10.3389/fcvm.2020.00020
11. Kobalava Zh.D., Konradi A.O., Nedogoda S.V., Shlyakhto E.V., Arutyunov G.P., Baranova E.I. et al. 2024 Clinical practice guidelines for Hypertension in adults // Russian Journal of Cardiology. – 2024; 29:6117. https: //doi.org/10.15829/1560-4071-2024-6117
12. Салухов В.В., Галстян Г.Р., Ильинская Т.А. Практические аспекты инициации и применения ингибиторов SGLT2 в стационаре и на амбулаторном этапе // Сахарный диабет. – 2022 – Т. 25, № 3 – С. 275–287. Doi:https://doi.org/10.14341/DM12855
13. Салухов В.В., Котова М.Е. Основные эффекты, вызываемые ингибиторами SGLT2 у больных сахарным диабетом типа 2, и механизмы, которые их определяют // Эндокринология. Новости. Мнения. Обучение. – 2019 – Т. 8, № 3(28). – С. 61–74. Doi:https://doi.org/10.24411/2304-9529-2019-1300714 Салухов В.В., Ильинская Т.А., Минаков А.А. Влияние современной сахароснижающей терапии на массу тела у больных сахарным диабетом 2 типа // Эндокринология. Новости. Мнения. Обучение. – 2022 – Т. 11 – № 1(38). – С. 39–52. Doi:https://doi.org/10.33029/2304-9529-2022-11-1-39-52
14. Cai Y., Shi W., Xu G. The efficacy and safety of SGLT2 inhibitors combined with ACEI/ARBs in the treatment of type 2 diabetes mellitus: A meta-analysis of randomized controlled studies // Expert Opin Drug Saf. – 2020; 19:1497–504. https: //doi.org/10.1080/14740338.2020.1817378
15. Lopaschuk G.D., Verma S. Mechanisms of Cardiovascular Benefits of Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors: A State-of-the-Art Review // JACC Basic Transl Sci. – 2020; 5:632– 44 https: //doi.org/10.1016/j.jacbts.2020.02.004
16. Basalay M.V., Korsak A., He Z., Gourine A.V., Davidson S.M., Yellon D.M. SGLT2 Inhibition Induces Cardioprotection by Increasing Parasympathetic Activity // Circ Res. – 2025; 136:229–31. https: //doi.org/10.1161/CIRCRESAHA.124.324708
17. Kounatidis D., Vallianou N., Evangelopoulos A., Vlahodimitris I., Grivakou E., Kotsi E. et al. SGLT-2 Inhibitors and the Inflammasome: What’s Next in the 21st Century? // Nutrients. – 2023; 15:2294. https: //doi.org/10.3390/nu15102294
18. Gong S., Sui Y., Xiao M., Fu D., Xiong Z., Zhang L. et al. Canagliflozin Mediates Mitophagy Through the AMPK/PINK1/Parkin Pathway to Alleviate ISO-induced Cardiac Remodeling // J Cardiovasc Pharmacol. – 2024; 84:496–505. https: //doi.org/10.1097/FJC.0000000000001625
19. Hoehlschen J., Hofreither D., Tomin T., Birner-Gruenberger R. Redox-driven cardioprotective effects of sodium-glucose co-transporter-2 inhibitors: comparative review // Cardiovasc Diabetol. – 2023; 22:101. https: //doi.org/10.1186/s12933-023-01822-7.
20. Camilli M., Viscovo M., Maggio L., Bonanni A., Torre I., Pellegrino C. et al. Sodium–glucose cotransporter 2 inhibitors and the cancer patient: from diabetes to cardioprotection and beyond // Basic Res Cardiol. – 2024; 120:241–62. https: //doi.org/10.1007/s00395-024-01059-9 22 Kapadia P., Bikkina P., Landicho M.A., Parekh S., Haas M.J., Mooradian A.D. Effect of anti- hyperglycemic drugs on endoplasmic reticulum (ER) stress in human coronary artery endothelial cells // Eur J Pharmacol. – 2021; 907:174249. https: //doi.org/10.1016/j.ejphar.2021.174249
21. Trum M., Riechel J., Wagner S. Cardioprotection by SGLT2 Inhibitors – Does It All Come Down to Na+? // Int J Mol Sci. – 2021; 22:7976. https: //doi.org/10.3390/ijms22157976
22. Cotton M., Hawley A. SGLT2 Inhibitors; Suggested Mechanism of Actions in Supporting Post- Myocardial Infarction Patients // Future Cardiol. – 2023; 19:419–22. https: //doi.org/10.2217/fca-2023- 0066
23. Mylonas N., Nikolaou P.E., Karakasis P., Stachteas P., Fragakis N., Andreadou I. Endothelial Protection by Sodium-Glucose Cotransporter 2 Inhibitors: A Literature Review of In Vitro and In Vivo Studies // Int J Mol Sci. – 2024; 25 https: //doi.org/10.3390/ijms25137274
24. Vafa R.G., Sabahizadeh A., Mofarrah R. Guarding the heart: How SGLT-2 inhibitors protect against chemotherapy-induced cardiotoxicity // Curr Probl Cardiol. – 2024; 49:102350. https: //doi.org/10.1016/j.cpcardiol.2023.102350
25. Oh C.-M., Cho S., Jang J.-Y., Kim H., Chun S., Choi M. et al. Cardioprotective Potential of an SGLT2 Inhibitor Against Doxorubicin-Induced Heart Failure // Korean Circ J. – 2019; 49:1183. https: //doi.org/10.4070/kcj.2019.0180
26. Ma S., He L.-L., Zhang G.-R., Zuo Q.-J., Wang Z.-L., Zhai J.-L. et al. Canagliflozin mitigates ferroptosis and ameliorates heart failure in rats with preserved ejection fraction // Naunyn Schmiedebergs Arch Pharmacol. – 2022; 395:945–62. https: //doi.org/10.1007/s00210-022-02243-1
27. Kasperova B.J., Mraz M., Svoboda P., Hlavacek D., Kratochvilova H., Modos I. et al. Sodium-glucose cotransporter 2 inhibitors induce anti-inflammatory and anti-ferroptotic shift in epicardial adipose tissue of subjects with severe heart failure // Cardiovasc Diabetol. – 2024; 23:223. https: //doi.org/10.1186/s12933-024-02298-9
28. Wright E.M. SGLT2 and cancer // Pflugers Arch. – 2020; 472:1407–14. https: //doi.org/10.1007/s00424-020-02448-4
29. Dutka M., Bobiński R., Francuz T., Garczorz W., Zimmer K., Ilczak T. et al. SGLT-2 Inhibitors in Cancer Treatment-Mechanisms of Action and Emerging New Perspectives // Cancers (Basel). – 2022; 14 https: //doi.org/10.3390/cancers14235811
30. Dabour M.S., George M.Y., Daniel M.R., Blaes A.H., Zordoky B.N. The Cardioprotective and Anticancer Effects of SGLT2 Inhibitors // JACC CardioOncol. – 2024; 6:159–82. https: //doi.org/10.1016/j.jaccao.2024.01.007
31. Correale M., Lamacchia O., Ciccarelli M., Dattilo G., Tricarico L., Brunetti N.D. Vascular and metabolic effects of ИНГЛТ-2 and GLP-1 in heart failure patients // Heart Fail Rev. – 2021; 28:733–44. https: //doi.org/10.1007/s10741-021-10157-y
32. Fath A.R., Aglan M., Aglan A., Chilton R.J., Trakhtenbroit A., Al-Shammary O.A. et al. Cardioprotective Potential of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Cancer Treated With Anthracyclines: An Observational Study // Am J Cardiol. – 2024; 222:175–82. https: //doi.org/10.1016/j.amjcard.2024.04.032
33. Abdel-Qadir H., Carrasco R., Austin P.C., Chen Y., Zhou L., Fang J. et al. The Association of Sodium- Glucose Cotransporter 2 Inhibitors With Cardiovascular Outcomes in Anthracycline-Treated Patients With Cancer // JACC CardioOncol. – 2023; 5:318–28. https: //doi.org/10.1016/j.jaccao.2023.03.011
34. Hwang H.-J., Kim M., Jun J.E., Yon D.K. Sodium-glucose cotransporter-2 inhibitors improve clinical outcomes in patients with type 2 diabetes mellitus undergoing anthracycline-containing chemotherapy: an emulated target trial using nationwide cohort data in South Korea // Sci Rep. – 2023; 13:21756. https: //doi.org/10.1038/s41598-023-48678-1
35. Gongora C.A., Drobni Z.D., Quinaglia Araujo Costa Silva T., Zafar A., Gong J., Zlotoff D.A. et al. Sodium-Glucose Co-Transporter-2 Inhibitors and Cardiac Outcomes Among Patients Treated With Anthracyclines // JACC Heart Fail. – 2022; 10:559–67. https: //doi.org/10.1016/j.jchf.2022.03.006
36. Tabowei G., Dadzie S.K., Perswani P., Nawaz S., Kaur M., Moqattash M. et al. Efficacy of Sodium- Glucose Cotransporter 2 Inhibitors in Preventing Heart Failure in Patients Receiving Anthracycline-Based Cancer Therapy: A Systematic Review and Meta-Analysis // Cureus. //doi.org/10.7759/cureus.60086
37. Chiang C.-H., Chiang C.-H., Chiang C.-H., Ma K.S.-K., Peng C.-Y., Hsia Y.P. et al. Impact of sodium- glucose cotransporter-2 inhibitors on heart failure and mortality in patients with cancer // Heart. – 2023; 109:470–7. https: //doi.org/10.1136/heartjnl-2022-321545
38. Perelman M.G., Brzezinski R.Y., Waissengrin B., Leshem Y., Bainhoren O., Rubinstein T.A. et al. Sodium-glucose co-transporter-2 inhibitors in patients treated with immune checkpoint inhibitors // Cardio-Oncology. – 2024; 10:2. https: //doi.org/10.1186/s40959-023-00199-6
39. Chong J.H., Chang W.-T., Chan J.J., Tan T.J.Y., Chan J.W.K., Wong M. et al. The cardioprotective potential of sodium-glucose cotransporter 2-inhibitors in breast cancer therapy-related cardiac dysfunction – A systematic review // Curr Probl Cardiol. – 2024; 49:102372. //doi.org/10.1016/j.cpcardiol.2024.102372
40. Agarwal S., Qamar U., Fujiwara Y., Guha A., Naqash A.R., Yang E.H. et al. The Effect of Sodium- Glucose Cotransporter-2 Inhibitors on Cardiovascular Outcomes in Patients With Cancer: A Systematic Review and Meta-Analysis // Am J Cardiol. – 2024; 216:87–90. //doi.org/10.1016/j.amjcard.2024.01.032
41. Avula V., Sharma G., Kosiborod M.N., Vaduganathan M., Neilan T.G., Lopez T. et al. SGLT2 Inhibitor Use and Risk of Clinical Events in Patients With Cancer Therapy–Related Cardiac Dysfunction // JACC Heart Fail. – 2024; 12:67–78. https: //doi.org/10.1016/j.jchf.2023.08.026
42. Quagliariello V., De Laurentiis M., Rea D., Barbieri A., Monti M.G., Carbone A. et al. The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin // Cardiovasc Diabetol. – 2021; 20:150. https: //doi.org/10.1186/s12933-021-01346-y
43. Barış V.Ö., Dinçsoy A.B., Gedikli E., Zırh S., Müftüoğlu S., Erdem A. Empagliflozin Significantly Prevents the Doxorubicin-induced Acute Cardiotoxicity via Non-antioxidant Pathways // Cardiovasc Toxicol. – 2021; 21:747–58. https: //doi.org/10.1007/s12012-021-09665-y
44. Maurea N., Quagliariello V., De Laurentiis M., Cavalcanti E., Paccone A., Buccolo S. et al. The SGLT-2 inhibitor dapagliflozin reduces cell death and apoptosis in cardiomyocytes exposed to trastuzumab and doxorubicin through NLRP3-mediated pathways // Journal of Clinical Oncology. – 2021; 39:e15041–e15041. https: //doi.org/10.1200/JCO.2021.39.15_suppl.e15041
45. Refaie M.M.M., Shehata S., El-Hussieny M., Fawzy M.A., Ahmed N.Z.M., Marey H. et al. Molecular mechanism of empagliflozin cardioprotection in 5-fluorouracil (5-FU)-induced cardiotoxicity via modulation of SGLT2 and TNFα/TLR/NF-κB signaling pathway in rats // Toxicol Res. – 2024; 40:139– 51 https: //doi.org/10.1007/s43188-023-00204-1
46. Empagliflozin in the Prevention of Cardiotoxicity in Cancer Patients Undergoing Chemotherapy Based on Anthracyclines (EMPACT). https: //ClinicaltrialsGov/Study/NCT05271162 n.d.
47. Ionică L.N., Lința A.V., Bătrîn A.D., Hâncu I.M., Lolescu B.M., Dănilă M.D. et al. The Off-Target Cardioprotective Mechanisms of Sodium–Glucose Cotransporter 2 Inhibitors: An Overview // Int J Mol Sci. – 2024; 25:7711. https: //doi.org/10.3390/ijms25147711.
48. Tentolouris A., Vlachakis P., Tzeravini E., Eleftheriadou I., Tentolouris N. SGLT2 Inhibitors: A Review of Their Antidiabetic and Cardioprotective Effects // Int J Environ Res Public Health. – 2019; 16:2965. https: //doi.org/10.3390/ijerph16162965
49. Nikolaou P.E., Mylonas N., Makridakis M., Makrecka-Kuka M., Iliou A., Zerikiotis S. et al. Cardioprotection by selective SGLT-2 inhibitors in a non-diabetic mouse model of myocardial ischemia/reperfusion injury: a class or a drug effect? // Basic Res Cardiol. – 2022; 117:27. https: //doi.org/10.1007/s00395-022-00934-7
50. Soares R.R., Viggiani L.F., Reis Filho J.M., Joviano-Santos J.V. Cardioprotection of Canagliflozin, Dapagliflozin, and Empagliflozin: Lessons from preclinical studies // Chem Biol Interact. – 2024; 403:111229. https: //doi.org/10.1016/j.cbi.2024.111229
